Description
The insect cell expression market is estimated to be valued at USD 292.4 Million in 2021 and is poised to grow at a significant CAGR of 12.4% over 2022-2028. Insect cells offer high levels of protein expression with posttranslational modification approaching that of mammalian cells, ease of scale-up, and simplified cell growth that can be readily adapted to high-density suspension culture for large-scale expression. Based on product type the global insect cell expression market is segmented into reagents, expression vectors, competent cells, instruments, and services. Regents segment anticipated to hold largest market share and the growth of this segment is attributed to the rising incidences of increasing research activities in the field of protein expression and the large-scale production of antibodies and vaccines. Furthermore, based on the application the global insect cell expression market is segmented into therapeutic applications, industrial applications, and research applications. The therapeutic application segment accounted to grow at a significant CAGR over the forecast years owing to a surge in the prevalence of chronic diseases coupled with the increase in the R&D for the novel therapeutics by the market players across the globe. Increasing in demand for protein biologics, growth in the geriatric population, rise in the life science and biopharmaceutical industries, increasing research activities on recombinant-based protein expression, and availability of funding for protein-based research are anticipated to propel the growth of market over the forecast years.
Recent Market Developments:
In 2020, Thermo Fisher’s launched ExpiSf Expression System, which Offers 3X Higher Protein Yields in a Shorter Time. The ExpiSf Expression System is a complete chemically defined baculovirus-insect cell protein expression system that delivers superior yields.
In May 2019, Oxford expression Technologies Ltd launched BaculaQuant All in one titration of recombinant Baculoviruses, features includes Titre accuracy comparable to plaque assay method and Compatible with any AcMNPV-based baculovirus system containing gp64 virus gene.
Reviews
There are no reviews yet.